# Entrada Therapeutics share price today (Entrada Therapeutics, Inc., TRDA)

> Entrada Therapeutics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. TRDA · Healthcare · Biotechnology · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/trda

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $4.72 (−32.1% in a year)
- Revenue (Jun 2026): ₹0.0 B
- Profit (Jun 2026), incl. one-off: ₹0.0 B (one-off item, see below)
- ROE: −47%, FY25

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Entrada Therapeutics share price today? Entrada Therapeutics, Inc.'s share price was $4.72 at the close on 3 November 2026. That is 45.8% below its average price over the last 200 trading days. In the last 52 weeks it traded between $4 and $15, and at that close it sat 3% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 8 weeks running. Over the last 1 year the share price moved −28% while the S&P 500 moved +21%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 11 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Entrada Therapeutics pay? Entrada Therapeutics, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Entrada Therapeutics on? Entrada Therapeutics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Entrada Therapeutics profitable? Entrada Therapeutics, Inc. posted a net loss of ₹0.04 B in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY25 year was a loss of ₹0.1 B. That loss is 4,762.0% of the quarter's revenue. The same quarter a year earlier lost ₹0.04 B. 8 of the last 12 reported quarters were loss-making. Jun 2026 profit was ₹0.0 B. For the full year, FY25 profit was −₹0.1 B (−319.0% on the year before). Read this profit with care: at ₹0.0 B it is bigger than the quarter's whole revenue of ₹0.0 B. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −5,007.0% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## How much revenue does Entrada Therapeutics make, and is it growing? Entrada Therapeutics, Inc. reported ₹0.0 B of revenue in the Jun 2026 quarter, −53.9% on the same quarter a year earlier. Over 2 years it has grown −55.6% a year on average. The last full year, FY25, came in at ₹0.0 B. The last four reported quarters add to ₹0.0 B. FY25 revenue was ₹0.0 B, −87.9% on the year before. Recent pace: the last four quarters grew −84.5% on average, against −55.6% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −94.1%, against −86.0% a year over the last 8 quarters (rolling over). This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## How much of its sales does Entrada Therapeutics keep? Entrada Therapeutics, Inc.'s sales have fallen to very little: FY25 revenue was ₹0.0 B, against ₹0.2 B in FY24. On sales that small an operating margin is not a useful reading, so this section is left out until sales recover. ## Is Entrada Therapeutics' profit turning into cash? Entrada Therapeutics, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used ₹0.1 B of cash, against −₹0.1 B of profit. After ₹0.0 B of spending on assets, free cash was −₹0.1 B: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: it spends almost nothing on new assets, so the cash goes on running the business. The next section shows the spending figures. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## Where does Entrada Therapeutics' cash go? Entrada Therapeutics, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent ₹0.0 B on assets over the last 3 years. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: ₹0.0 B over the last 3 years. In short: almost nothing is being spent on new assets, so the cash goes on running the business. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## What is Entrada Therapeutics' P/E ratio, and how does it compare with its own history? Entrada Therapeutics, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. The P/E comes back here once profit turns positive. ## Is the Entrada Therapeutics business getting better or worse? Entrada Therapeutics, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 10 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Entrada Therapeutics earn on its capital? Entrada Therapeutics, Inc. earned a ROE of −47% in FY25. Its return on capital used (ROIC) is left out: on sales this small it reads −1,165%, a number that says nothing useful about the business. ## Does Entrada Therapeutics have too much debt? Entrada Therapeutics, Inc. has total debt of ₹0.0 B against shareholder equity of ₹0.2 B as of Jun 2026, so its debt is 0.21× its equity, which is very little. Year by year, that ratio went from 0.12 in FY22 to 0.17 in FY25. So the returns on this page come from the business, not from borrowed money. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## What is the Entrada Therapeutics shareholding pattern? 14.4% of Entrada Therapeutics, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 9.5 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Entrada Therapeutics from balance-sheet trouble? For Entrada Therapeutics, Inc., the Z-score is 0.16. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 0.16 is inside the danger zone, so the balance sheet is a real risk. ## How does Entrada Therapeutics rank in its industry? There is no score against its industry: Entrada Therapeutics, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Entrada Therapeutics compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Entrada Therapeutics in size? Entrada Therapeutics is the 201st largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Upstream Bio, Inc., Whitehawk Therapeutics, Inc. and Invivyd, Inc. Just below it: Adagene Inc., Sutro Biopharma, Inc. and Cue Biopharma, Inc. ### Biotechnology companies close in size

1. [Upstream Bio, Inc.](https://www.sectoralpha.in/us/stocks/upb) $186 million
2. [Whitehawk Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/whwk) $177 million
3. [Invivyd, Inc.](https://www.sectoralpha.in/us/stocks/ivvd) $171 million
4. Entrada Therapeutics, Inc. $170 million
5. [Adagene Inc.](https://www.sectoralpha.in/us/stocks/adag) $158 million
6. [Sutro Biopharma, Inc.](https://www.sectoralpha.in/us/stocks/stro) $158 million
7. [Cue Biopharma, Inc.](https://www.sectoralpha.in/us/stocks/cue) $152 million

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

## What else do people ask about Entrada Therapeutics? ### What were Entrada Therapeutics's latest quarterly results? Entrada Therapeutics, Inc. reported revenue of ₹0.0 B and a net loss of ₹0.0 B for the Jun 2026 quarter. The operating margin was −5,007.0%, 2,604.5 percentage points lower than a year earlier (as of 3 November 2026). ### What is Entrada Therapeutics's market cap? Entrada Therapeutics, Inc.'s market capitalisation is $170 M at a stock price of $4.72. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Entrada Therapeutics performing? Entrada Therapeutics, Inc.'s latest readings are below. Over the past 13 weeks it has done worse than the S&P 500, for 8 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Entrada Therapeutics's stock price go up? This page does not forecast Entrada Therapeutics, Inc.'s stock price. What it shows instead: the stock price is $4.72. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### What could break the Entrada Therapeutics story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Entrada Therapeutics a stock worth studying right now? What the numbers show: Entrada Therapeutics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.